Hillmen Analyzes Current and Upcoming Trials of BTK InhibitorsByPeter Hillmen, MBChB, PhDFebruary 24th 2021During a Targeted Oncology Case-Based Peer Perspectives event, Peter Hillmen, MBChB, PhD, discussed the case of 61-year-old patient with diffuse infiltration by chronic leukocytic leukemia.